Merida Biosciences
Catherine Deatherage, PhD, serves as a Senior Scientist in Formulation and Drug Product Manufacturing at Merida Biosciences since March 2025. Prior to this role, Catherine held positions as a Senior Scientist at Kisbee Therapeutics focusing on Drug Product Development and at Elevian, Inc., where work concentrated on protein biochemistry for aging-related therapeutics. Earlier experience includes a Postdoctoral Research Fellowship at Yale University School of Medicine, where research involved reconstituting the retromer-dependent endosomal sorting system, and a Graduate Student role at Vanderbilt University, where Catherine determined the 3-D atomic structure of Notch1. Initial experience includes a Post-Baccalaureate Fellowship at the National Cancer Institute, focusing on NMR methodology and protein analysis. Catherine earned a PhD in Biochemistry from Vanderbilt University and a BS in Chemistry from the University of South Dakota.
This person is not in any teams
This person is not in any offices
Merida Biosciences
Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.